Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study

Biology of Blood and Marrow Transplantation(2020)10.1016/j.bbmt.2020.06.012Source: DataRank Database

Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study is a research paper published in Biology of Blood and Marrow Transplantation (2020). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access35 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 3.19)OA: hybridTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Marianna Zahurak ORCID,Leo Luznik,Richard F. Ambinder ORCID,Ephraim J. Fuchs ORCID,Javier Bolaños‐Meade ORCID

Live enrichment

PubMed:32592857 PMC:PMC7486273 OpenAlex:https://openalex.org/W3037715654

NCI NIH HHS

Grant: T32 CA009071

NCI NIH HHS

Grant: P01 CA225618

NCI NIH HHS

Grant: P30 CA006973

National Institutes of Health

Society for Immunotherapy of Cancer

FWCI

3.19

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.bbmt.2020.06.012

HYBRIDhttps://doi.org/10.1016/j.bbmt.2020.06.012

publisherhttps://doi.org/10.1016/j.bbmt.2020.06.012

publisherhttps://api.elsevier.com/content/article/PII:S1083879120303670?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1083879120303670?httpAccept=text/plain

Fields of Study

Lymphoma Diagnosis and TreatmentImmune Cell Function and InteractionHematopoietic Stem Cell TransplantationMedicine

MeSH Terms

Immune Checkpoint InhibitorsCyclophosphamideGraft vs Host DiseaseHodgkin DiseaseHumansRetrospective StudiesTransplantation, HomologousTransplantation Conditioning

Keywords

MedicineHazard ratioInternal medicineCyclophosphamideCumulative incidenceIncidence (geometry)Retrospective cohort studyChemotherapyTransplantationGraft-versus-host diseaseSurgeryCohortGastroenterologyConfidence intervalEngraftmentGraft-versus-host-disease (Gvhd)Immune Checkpoint Inhibitors (Icis)Allogeneic Blood Or Marrow Transplantation (Allobmt)Post-transplantation Cyclophosphamide (Ptcy)Classic Hodgkin Lymphoma (Chl)

Sustainable Development Goals

SDG 0: Good health and well-being